|

Vedolizumab Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Entyvio, Immunoglobulin G1, anti-(human integrin LPAM-1 (lymphocyte Peyer''s patch adhesion molecule 1)) (human-Mus musculus heavy chain), disulfide with human-Mus musculus kappa-chain, dimer, Immunoglobulin G1, anti-(human integrin LPAM-1 (lymphocyte Peyer's patch adhesion molecule 1)) (human-Mus musculus heavy chain), disulfide with human-Mus musculus kappa-chain, dimer, LDP 02, LDP-02 +3 more

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • M.D. Anderson Cancer Center1
  • City of Hope Medical Center1

Indications

  • Cancer2
  • Graft-versus-host-disease1
  • Stage 0 Lung Cancer AJCC v81
  • Pathologic Stage IIID Cutaneous Melanoma AJCC v81
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v81

Duarte, California1 trial

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2

Houston, Texas1 trial

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

M D Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.